4.7 Article

Effects of Danhong injection on dyslipidemia and cholesterol metabolism in high-fat diets fed rats

期刊

JOURNAL OF ETHNOPHARMACOLOGY
卷 274, 期 -, 页码 -

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.jep.2021.114058

关键词

Danhong injection; Dyslipidemia; Hyperlipidemia; Oxidative stress; Cholesterol metabolism

资金

  1. National Science Foundation of China [81874366, 81873226, 81803992]
  2. Natural Science Foundation of Zhejiang Province [LZ17H270001, LR19H280001, LQ19H270001]

向作者/读者索取更多资源

The study demonstrated that Danhong injection (DHI) significantly improved hyperlipidemia in high-fat diet-fed rats by reducing lipid levels, decreasing hepatic lipid accumulation, improving liver function, and reducing oxidative stress. The potential mechanism may involve the promotion of bile acid synthesis through the activation of the PPAR alpha-LXR alpha-CYP7A1 pathway.
Ethnopharmacological relevance: Danhong injection (DHI) is a Chinese medical injection applied to the clinical treatment of cardiovascular diseases that has anti-inflammatory, antiplatelet aggregation and antithrombotic effects. This study aimed to explore the effects of DHI on dyslipidemia and cholesterol metabolism in high-fat diet-fed rats. Methods: Sprague Dawley (SD) rats were randomly divided into six groups: normal group (Normal); hyperlipidemia model group (Model); DHI-treated groups at doses of 1.0 mL/kg, 2.0 mL/kg, 4.0 mL/kg; and simvastatin positive control group (2.0 mg/kg). The hypolipidemic effects of DHI were evaluated by measuring serum lipid levels, hepatic function and oxidative stress, respectively. And pathological changes in liver tissues were determined using hematoxylin-eosin (H&E) and oil red O staining. Moreover, the mRNA and protein expression levels of cholesterol metabolism related genes were detected by real-time PCR (RT-PCR) and Western blot. Results: Compared with the Model group, DHI treatment markedly decreased the liver index and improved the pathological morphology of liver tissues. DHI treatment dose-dependently decreased the levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), malondialdehyde (MDA), and free fatty acids (FFA) in serum or liver tissues (P < 0.01 or P < 0.05), and increased the high-density lipoprotein cholesterol (HDL-C) and tripeptide glutathione (GSH) (P < 0.01 or P < 0.05). The activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) were increased in the DHI-treated groups (P < 0.01 or P < 0.05), while the alanine transaminase (ALT) and aspartate transaminase (AST) were decreased (P < 0.01 or P < 0.05). Furthermore, the expression levels of LDL receptor (LDLR), cholesterol 7-alpha-hydroxylase (CYP7A1), liver X receptor alpha (LXR alpha), and peroxisome proliferator-activated receptor alpha (PPAR alpha) were dose-dependently upregulated in the DHI-treated groups, whereas the expression of sterol regulatory element-binding protein-2 (SREBP-2) was downregulated. Conclusions: Our study demonstrated that DHI markedly ameliorated hyperlipidemia rats by regulating serum lipid levels, inhibiting hepatic lipid accumulation and steatosis, improving hepatic dysfunction, and reducing oxidative stress. The potential mechanism was also tentatively investigated and may be related to the promotion of bile acid synthesis via activation of the PPAR alpha-LXR alpha-CYP7A1 pathway. Therefore, DHI could be regarded as a potential hypolipidemic drug for the treatment of hyperlipidemia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据